A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

NCT04797468 · clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped The Early Termination is the result of the sponsor's need to reevaluate the study design and to make needed vendor realignments.

Conditions

Interventions

Sponsor

Shanghai Henlius Biotech